Foundation Fighting Blindness Retinal Degeneration Fund sold $7.4M of Opus Genetics (IRD)

Executed May 18, disclosed May 20, 2 days later.

Value, as filed

$7.4M

1,700,000 sh × $4.35

Executed

May 18

the trade date, as filed

Disclosed

May 20

2 days after the trade

Return, 21 sessionsiFrom the disclosed entry session; derived

–

purchases only

Returns are measured on stock purchases only.

The filer

FF Foundation Fighting Blindness Retinal Degeneration Fund Director profile →

Foundation Fighting Blindness Retinal Degeneration Fund (Director) filed 2 Form 4 reports as a reporting entity in the trailing twelve months (0 purchases, 2 sales), most often in Opus Genetics, Inc. (IRD). The largest single filing was $8.6M of IRD (4,000,000 sh × $2.15, as filed), executed Dec 9 2025.

The name

IRD Opus Genetics, Inc. IRD · Healthcare · 5 filings in 24 months ticker →

Healthcare · Opus Genetics, Inc., a clinical-stage biopharmaceutical company, develops gene therapies to restore vision and prevent blindness in patient…

More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→

Other filings by Foundation Fighting Blindness Retinal Degeneration Fund in IRD

IRDSALE Opus Genetics, Inc. $8.6M
4,000,000 sh × $2.15
Exec Dec 9 2025
Filed Dec 11 2025 · 5:30 PM ET